| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to… |
date change Primary completion pushed: 2026-05-22 -> 2032-07-12 |
| 2026-06-12 | NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to… |
date change Completion pushed: 2031-08-14 -> 2032-07-12 |
| 2026-06-11 | NCT07015242 A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line… |
Trial sites reduced: 82 -> 40 locations |
| 2026-06-09 | NCT06672523 A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of… |
date change Primary completion pushed: 2026-04-20 -> 2027-10-25 |
| 2026-06-09 | NCT06672523 A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of… |
date change Completion pushed: 2026-04-20 -> 2027-10-25 |
| 2026-06-06 | NCT07063745 A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and… |
Trial sites expanded: 288 -> 311 locations |
| 2026-06-05 | NCT04895709 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With… |
Primary endpoint(s) modified |
| 2026-06-05 | NCT04895709 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With… |
Enrollment increased: 949 -> 1109 participants |
| 2026-06-05 | NCT04895709 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With… |
Trial arms changed: 7 -> 9 |
| 2026-06-05 | NCT04895709 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With… |
date change Primary completion pushed: 2028-07-07 -> 2031-08-31 |
| 2026-06-05 | NCT04895709 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With… |
date change Completion pushed: 2028-07-07 -> 2031-08-31 |
| 2026-06-05 | NCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes… |
Trial sites expanded: 74 -> 78 locations |
| 2026-06-04 | NCT07076121 A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-04 | NCT07076121 A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and… |
Trial sites reduced: 279 -> 269 locations |
| 2026-06-03 | NCT07291076 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With… |
Enrollment increased: 129 -> 198 participants |
| 2026-06-03 | NCT07291076 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With… |
Trial arms changed: 6 -> 7 |
| 2026-06-03 | NCT07291076 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With… |
Trial sites expanded: 50 -> 59 locations |
| 2026-06-03 | NCT03435796 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells |
Trial sites expanded: 200 -> 205 locations |
| 2026-06-03 | NCT07175285 A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response… |
Trial sites expanded: 58 -> 62 locations |
| 2026-06-03 | NCT07441408 Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in… |
Trial sites expanded: 216 -> 272 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07636863 Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig | Completed | |
| 2026-06-05 | NCT07629999 Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in… | Phase 1 | Not Yet Recruiting |
| 2026-05-22 | NCT07603557 Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) | Phase 2 | Not Yet Recruiting |
| 2026-05-20 | NCT07599007 Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small… | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic… | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07221877 | A Study to Evaluate the Effect of KarXT on Urological Safety | Schizophrenia | Recruiting |
| NCT07459543 | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose… | Untreated Melanoma | Not Yet Recruiting |
| NCT07004972 | A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India… | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Active, Not Recruiting |
| Phase 3 | |||
| NCT04877288 | A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney… | Renal Allograft Recipients | Recruiting |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy… | Multiple Myeloma | Recruiting |
| NCT06951698 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes… | Bipolar-I Disorder With Mania or Mania With Mixed Features | Recruiting |
| NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in… | Multiple Sclerosis, Relapsing-Remitting | Recruiting |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06882785 | A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult… | Schizophrenia | Recruiting |
| NCT07335562 | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel /… | Systemic Sclerosis | Recruiting |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs… | Non-small Cell Lung Cancer | Recruiting |
| NCT06911502 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab… | Follicular Lymphoma | Recruiting |
| NCT07116967 | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With… | Plaque Psoriasis | Recruiting |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… | Myelodysplastic Syndromes (MDS) | Recruiting |
| NCT06976216 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment… | Alzheimer's Disease | Recruiting |
| NCT06979453 | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165)… | Plaque Psoriasis | Recruiting |
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed… | Extensive-Stage Small Cell Lung Cancer | Recruiting |
| NCT06929273 | A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in… | Bipolar Disorder Type I With Mania | Recruiting |
| NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in… | Alzheimer Disease | Recruiting |
| NCT06947941 | A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis… | Alzheimer Disease | Recruiting |
| NCT07288567 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia… | Schizophrenia | Recruiting |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With… | Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in… | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting |